Posts

Posted on

Gold Standard Ventures Announces 2021 Exploration and Development Program

VANCOUVER, British Columbia, May 20, 2021 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (NYSE AMERICAN: GSV) (TSX: GSV) (“Gold Standard” or the “Company”) today announced plans for the 2021 exploration and development program on its vast land package in Nevada’s Carlin Trend. The program includes approximately 7,880 meters of reverse-circulation (“RC”) and core drilling over 46 holes. Drilling is anticipated to start in May 2021.

(https://goldstandardv.com/site/assets/files/4499/2021_exploration_and_development_program.pdf)


Exploration Focus Areas:

  • Pinion SB Zone: 7 RC drill holes (approximately 2,350 meters) to further develop oxide mineralization at the SB Zone target. Previously released intercepts at SB Zone include: PR20-26 (77.7m of 2.24 g Au/t), PR20-30 (50.3m of 1.04 g Au/t), PC20-22 (61.1m of 1.07 g Au/t) (see November 12, 2020 and April 15, 2021 releases for further details), and historical hole PIN14-38 (57.9m of 1.01 g Au/t); the deposit remain open to the south and east in this target zone.
  • Dark Star: 30 RC and core drill holes (approximately 3,900 meters) to define the limits of near-surface oxide mineralization at Dark Star Main, convert Inferred resources within the mine plan boundary to Measured or Indicated resources, and complete metallurgical core holes for test work in support of future mining and processing.
  • LT: 5 RC drill holes (approximately 580 meters) will continue to test for gold mineralization along the LT Fault, to the north of LT20-01 (24.3m of 0.73 g Au/t) and LT20-08 (30.5m of 0.78 g Au/t) (see October 29, 2020 news release for further details) and structural and stratigraphic targets centered around surface channel sampling conducted in 2020. Three-meter surface channel sampling highlighted 57m of 0.61 g Au/t centered around LT20-01 and the LT-Tesla Fault intersection. Additionally, surface sampling to the south identified 18m of 4.84 g Au/t along the Lotus-LT Fault intersection. Sampling, mapping, and drilling has identified a zone approximately 200 meters long associated with the LT Fault and structural intersections with the northeast striking Tesla and Lotus faults. The mineralization remains open to the north, south, west, and at depth.

Jason Attew, President and CEO, commented, “We are excited to initiate our 2021 drilling program. The focus of this year’s program is to test for extensions to both Pinion and Dark Star with the goal of enhancing the size of the pits and further extending the project life. Additionally, we will test the highly prospective LT zone which is near Pinion and Dark Star and has the potential to develop into a satellite pit in the future. Any success from this 2021 exploration program is distinct from and incremental to the upcoming South Railroad Project Feasibility Study.”

Other Exploration & Development Work:

  • Pinion: 4 RC drill holes (approximately 1,050 meters) to advance metallurgical and hydrology test work and support mine start-up.
  • South Dome: Exploration will focus on compiling results from the soil survey (2,700 samples) and geologic mapping completed in 2020. Work to date has identified a domal feature within Pinion stratigraphy that has elevated gold, silver, arsenic and mercury in soils. The goal is to advance the project to a drill decision by the end of year.

Sampling Methodology, Chain of Custody, Quality Control and Quality Assurance

All Gold Standard sampling was conducted under the supervision of the Company’s senior geologists and the chain of custody from the project to the sample preparation facility was continuously monitored. A blank, certified reference material, or rig duplicate was inserted approximately every tenth sample. Samples were delivered to Bureau Veritas Mineral Laboratories preparation facility in either Sparks, NV or Hermosillo, Mexico where they were crushed and pulverized. Resulting sample pulps were digested and analyzed for gold using fire assay fusion and an atomic absorption spectroscopy (AAS) finish on a 30-gram split. Over limit gold assays were determined using a fire assay fusion with a gravimetric finish on a 30-gram split. All other elements were determined by ICP in Vancouver, B.C. Data verification of the analytical results included a statistical analysis of the standards and blanks that must pass certain parameters for acceptance to insure accurate and verifiable results.

Drill hole deviation was measured by gyroscopic down hole surveys that were completed on all holes by International Directional Services of Elko, NV. Final drill collar locations are surveyed by differential GPS by Apex Surveying, LLC of Spring Creek, Nevada.

All third party laboratories and service providers used or retained in the analysis of the samples are independent of Gold Standard.

Qualified Persons

Richard Yancey, Geology Manager, is the Company’s Qualified Person (QP) as defined by National Instrument 43-101 and has reviewed and approved the technical contents of this news release.


About Gold Standard

Gold Standard is developing the South Railroad Project, an open pit, heap leach gold project located in Elko County, Nevada. The project is part of a +21,000 hectare land package on the Carlin Trend, and is 100% owned or controlled by Gold Standard. The goal of the Company is to become the low-cost junior producer of choice in Nevada, one of the premier mining jurisdictions in the world.


Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements, which relate to future events or future performance. All statements, other than statements of historical fact, included herein including, without limitation, statements regarding the potential for LT to be a satellite pit to the South Railroad Project (“SRP”); the ability of the Company to increase the resource base at Dark Star and Pinion; the nature and extent of mineralization at the Pinion and Dark Star deposits; the Company’s future exploration plans and objectives; the expected size and dimensions of the planned pits and area of demonstrated mineral resources of the SRP; and about the potential financing and construction of the SRP. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company, including that LT will become a satellite pit to the SRP; that the Company will be successful in increasing the resource base at Dark Star and Pinion; that the pit and the area of demonstrated mineral resources at SRP will conform to that set out in the preliminary feasibility study for SRP; and that the Company will be successful in the financing and construction of the SRP. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, among others: that LT will not become a satellite pit to the SRP; that the Company may not successfully increase the resource base at Dark Star and Pinion; that the pit and the area of demonstrated mineral resources at SRP will be different than that set out in the Preliminary Feasibility Study for SRP, as a result of the Company’s Feasibility Study or otherwise; that the Company may not be successful in financing and constructing the SRP; that the SRP may never be placed into production; global financial conditions and volatility of capital markets, uncertainty regarding the availability of additional capital, fluctuations in commodity prices; title matters; and the additional risks identified in our filings with Canadian securities regulators on SEDAR in Canada (available at www.sedar.com) and with the SEC on EDGAR (available at www.sec.gov/edgar.shtml). These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

For further information contact:

Michael McDonald
Vice President, Corporate Development & Investor Relations
Phone: 1-604-687-2766
E-Mail: [email protected]



Posted on

BIGtoken Expands Leadership Team Responsibilities – George Stella Appointed President

BIGtoken Expands Leadership Team Responsibilities – George Stella Appointed President

Will assume operations role in addition to serving as BIGtoken’s chief revenue officer.

LOS ANGELES–(BUSINESS WIRE)–
BIGtoken® Inc., the first privacy-focused, opt-in data marketplace where people own and monetize their data, announced today that George Stella has been appointed president of the company.

Mr. Stella, 50, was named BIGtoken’s chief revenue officer in February 2021, bringing more than 20 years of digital media experience. As a co-founder of BIGtoken, Mr. Stella was the architect of BIGtoken’s commercial product strategy and executed its go-to-market plan.

“We’re looking forward to George’s leadership at BIGtoken as we address the importance of consumers having control over their data,” said Christopher Miglino, chairman of the BIGtoken board and CEO of its former parent company SRAX (Nasdaq: SRAX). “He is intimately familiar with our strategy and is well-versed in the details of our product.”

As president of BIGtoken, Mr. Stella will be overseeing day-to-day operations in addition to fulfilling his responsibilities as chief revenue officer. He assumed these activities on May 19, 2021, following the departure of Lou Kerner. During his tenure as CRO, BIGtoken has counted nine of the top 10 CPG companies as repeat customers.

“I’m committed to executing BIGtoken’s original promise: to allow consumers to own and monetize their data,” said Mr. Stella. “I understand how critical data is for brands at this juncture, and we’re committed to making the best, most accurate first-party data for brands.”

Mr. Stella’s shopper marketing experience over the past seven years includes sales and media positions at OwnerIQ and HookLogic. Mr. Stella began his digital media career at 24/7 Real Media, where he spent more than 11 years as a sales director. Mr. Stella’s advertising career began at Comedy Central.

About BIGtoken

BIGtoken® believes that data privacy is a human right. BIGtoken is the first privacy focused, opt-in data marketplace where people own and monetize their data. Through a transparent platform and consumer reward system, BIGtoken offers users choice, transparency, and compensation for their anonymized data. Participating consumers earn rewards and advertisers and media companies get access to insights from compliant first-party data for marketing and media activation. For more information on BIGtoken, visit bigtoken.com.

Cautionary Statement Regarding Forward-Looking Information:

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in our business, and our need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in BIGtoken’s periodic reports filed with the Securities and Exchange Commission (SEC). We do not assume any obligation to update any forward-looking statements.

Natalie Santos

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Logo
Logo
Posted on

SADA Opens Global Delivery Center in Armenia

A first of its kind for SADA, the Center will provide professional services to SADA’s global customer base while advancing the technical skills of workers in the region

LOS ANGELES, Calif., May 20, 2021 (GLOBE NEWSWIRE) — SADA, a leading global business and technology consultancy, announces the opening of a Global Delivery Center (GDC) in Yerevan, Armenia. This is the first such facility established by SADA, whose international presence currently includes wholly owned subsidiaries in Canada and Ireland. The goal of the SADA GDC in Armenia is twofold: to provide additional delivery and support services to companies around the world that are adopting Google Cloud, and to develop the technical capabilities of aspiring IT workers in a region that is rapidly becoming a popular European technology hub.

According to a recent Forbes article, “Tech is now the largest foreign investment in Armenia and many of the world’s most powerful technology firms—including Intel, Microsoft, Google, IBM, Synopsys and Cisco—all have a physical presence there, as the country’s tech sector grew 33% in 2018 to become a $250 million a year industry.” Meanwhile, a recent LinkedIn article highlighted the need to develop Armenia’s IT workforce to support its burgeoning tech community.

SADA, whose co-founders Hovig and Annie Safoian, as well as CEO Tony Safoian, were born and raised in Armenia, has taken these messages to heart. Under the leadership of Hovig, who is Chairman of SADA’s Board of Directors, and Naira Khurshudyan, who is Managing Director of the GDC, SADA is aggressively recruiting workers with a background in technology. SADA is working closely with the Armenian government and local universities, and plans to hire at least 50 people at the GDC in Armenia within two years.

New GDC employees will participate in SADA’s novel training program, which includes guidance from certified cloud engineers and the opportunity to work alongside SADA’s U.S.-based teams in support of current customer projects. The SADA GDC is located at The Hub at Lovers Park in Yerevan.

“The GDC’s primary function will be as an engineering center of excellence for all SADA customers,” said Khurshudyan. “Our customers need ‘follow-the-sun’ capabilities to enhance our professional services in the areas of infrastructure modernization, Anthos and data engineering/analytics. The GDC will also provide key back-office support functions to assist in scaling our rapid growth.”

“SADA’s growth in the cloud market is demanding that we create new offerings to streamline setup and activation of Google Cloud,” said Tony Safoian, CEO of SADA, who has spoken about his excitement and vision for pursuing the GDC in Armenia. “With that in mind, the GDC will also serve as a ‘Technical Onboarding Center’ for all our customers, offering streamlined services that accelerate the initial steps for adopting Google Cloud Platform.”

About SADA

SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America’s Fastest Growing Private Companies for 14 straight years, and the 2021 Inc. list of America’s Top 50 Workplaces. More info at www.sada.com.

Media contact:
Kevin Wolf
TGPR
[email protected]



Posted on

Gainwell’s HMS Donates $20,000 to Girlstart to Support STEM Camps for Girls

IRVING, Texas, May 20, 2021 (GLOBE NEWSWIRE) — For the second year in a row, HMS, a Gainwell Technologies Company, announced it has donated $20,000 to Girlstart, an organization that designs and implements innovative, high-quality STEM (science, technology, engineering, and math) education programs for young girls nationwide.

Girlstart hosts programs throughout the year, including community STEM events, afterschool programs and their Girlstart Summer Camp each year.

This year, HMS’ donation will help fund the 2021 Summer Camp program by providing high-quality science kits for campers to build Micro:bits. These pocket-sized computers with LED displays, microphones, speakers and sensors allow children to explore how hardware and software work together. All the materials and tools required will be shipped to campers unable to attend in person.

“We are proud to support Girlstart’s mission of helping build the next generation of scientists, engineers and programmers,” said Jacob Sims, Gainwell’s chief technology officer and a member of Girlstart’s national board. “As we envision a more diverse and equitable society, the work Girlstart is doing to make STEM both accessible and fun for young girls is playing a major part in building the leaders of the future.”

Due to the ongoing COVID-19 pandemic, this year’s Girlstart Summer Camp will be a hybrid program, including virtual and in-person activities based on girls’ health, comfort level and regional public health regulations. Group sizes also will be limited, and additional measures taken to ensure a fun and safe experience for all campers.

With HMS’ donation, the program will be able to serve girls who otherwise could not afford to participate after a challenging year for many. The goal this year is to reach 850 campers and the theme is ‘Dream Mighty Dreams.’

“It means so much to receive this generous donation from HMS two years in a row,” said Tamara Hudgins, executive director for Girlstart. “With all the uncertainly heading into the summer of 2021, our hope was that if we couldn’t send all the girls to summer camp, then we could send summer camp to the girls. With support from donors like HMS, we were able to do just that.”

About Girlstart

Through its comprehensive programming, Girlstart provides a year-round, intensive suite of STEM education programs for K-12 girls. Girlstart’s core programs foster STEM skills development, an understanding of the importance of STEM as a way to solve the world’s major problems, as well as an interest in STEM electives, majors, and careers.

About HMS

HMS, a Gainwell Technologies Company, delivers healthcare technology and analytics solutions to reduce costs and make healthcare work better for payers, providers and members. Our first-in-class coordination of benefits and payment integrity solutions help our nation’s safety net programs save billions annually and ensure sustainability. Visit us at www.hms.com or follow us on LinkedIn and Twitter.

About Gainwell Technologies

Gainwell Technologies supports the administration and operations of health and human services programs with a broad range of eligibility, enrollment, claims processing and payment accuracy solutions. Together HMS and Gainwell serve hundreds of healthcare programs and have more than 90 years of proven experience and unapparelled industry expertise. Visit Gainwell at www.gainwelltechnologies.com.

Media Contact

Lacey Hautzinger
Senior Director, Corporate Marketing
HMS
(469) 284-7240
[email protected] 

 



Posted on

National Survey Shows Online Access and Telehealth are Keys to Patient Loyalty

National Survey Shows Online Access and Telehealth are Keys to Patient Loyalty

Recent Harris Poll Survey Confirms that Patients Seek the Convenience of Self Service and Welcome the Option to See Providers Virtually

ATLANTA–(BUSINESS WIRE)–
During the COVID-19 pandemic, patients became more aware of powerful options for accessing care and subsequently, the healthcare landscape may be irrevocably changed. Everything from self scheduling to precheck to actually seeing your provider in a virtual setting is not only possible, but seems to be practical and the preference for most patients. According to a new national survey conducted by the Harris Poll, on behalf of NextGen Healthcare, more than half of U.S. patients (53 percent) say the pandemic changed how they want to communicate with their doctor. Notably, nearly half (48 percent) indicate they would switch to a different healthcare provider if their current provider did not offer telehealth appointments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005327/en/

Recent Harris Poll Survey on behalf of NextGen Healthcare Confirms Patients Seek the Convenience of Self Service and Option to See Providers Virtually (Graphic: Business Wire)

Recent Harris Poll Survey on behalf of NextGen Healthcare Confirms Patients Seek the Convenience of Self Service and Option to See Providers Virtually (Graphic: Business Wire)

Pandemic Changes What Patients Expect from Their Doctor

The online survey of more than 2,000 U.S. adults, including 1,733 who typically see a healthcare provider annually (“patients”), generated insights into their experiences and preferences related to online healthcare tools, including:

Telehealth is here to stay. An overwhelming majority of U.S. patients who received telehealth services since March 2020 (84 percent) plan to continue using telehealth appointments in the future, citing reasons such as convenience (43 percent) or to avoid being around people who are ill (39 percent). Other insights include:

  • Telehealth can lead to better overall health by facilitating necessary ongoing and follow-up treatment: More than half of U.S. patients (57 percent) say they would be more likely to get follow-up medical care if telehealth appointments were an option.
  • Nearly 7 in 10 U.S. patients (69 percent) have seen a healthcare provider via telehealth since the COVID-19 pandemic began, with 46 percent meeting with a primary care physician (PCP) and 19 percent meeting with a mental healthcare provider. U.S. patients have also seen a women’s health provider (15 percent of women), ophthalmologist (9 percent), and orthopedist (7 percent) via telehealth.

Online access is a must.Nearly 6 in 10 U.S. patients (58 percent) would like to have more online access to their healthcare provider.Age plays a role in this:Patients from 18-54 are significantly more likely than patients 55 and older to say they would like to have more online access to their healthcare provider (68 percent vs. 43 percent). Topping the list of most important online services patients would look for if seeking a new provider are:

  • online appointment scheduling (49 percent)
  • ability to check-in or complete health forms/appointment paperwork online before an appointment (49 percent)
  • online prescription management (48 percent)
  • online medical records access (47 percent)

“We saw a tremendous surge in demand for digital communication capabilities during the pandemic—in fact, we enabled our network of more than 100,000 providers nationwide to engage in over 1.5 million virtual visits from March to December 2020 through our large enterprise and small practice solutions,” said John Beck, chief solutions officer for NextGen Healthcare. “These survey results confirmed that patients’ overall expectations for healthcare have shifted permanently. Integrated healthcare technology is good for the patient and good for the practice.”

Methodology

This survey was conducted online within the United States by The Harris Poll on behalf of NextGen Healthcare from March 25-29, 2021 among 2,055 U.S. adults ages 18 and older, among whom 1,733 are patients (defined as those who see a healthcare provider once a year or more often). This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact NextGen Healthcare.

Learn more about NextGen® Patient Experience Platform and NextGen Virtual Visits™.

About The Harris Poll

The Harris Poll is one of the longest running surveys in the U.S. tracking public opinion, motivations and social sentiment since 1963 that is now part of Harris Insights & Analytics, a global consulting and market research firm that delivers social intelligence for transformational times. We work with clients in three primary areas; building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible. To learn more, please visit www.theharrispoll.com.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Media Contact

Tami Stegmaier

NextGen Healthcare, Inc.

(949) 237-6083

[email protected]

Investor Relations Contact

Matthew Scalo

(415) 370-9202

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Technology Mental Health Dental Software Practice Management Internet Health General Health Data Management

MEDIA:

Logo
Logo
Photo
Photo
Recent Harris Poll Survey on behalf of NextGen Healthcare Confirms Patients Seek the Convenience of Self Service and Option to See Providers Virtually (Graphic: Business Wire)
Posted on

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences

— New clinical data accepted for oral and e-Poster presentation at
AACE —

— e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting —

NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29, 2021).

Oral presentations and posters for display are summarized below:


e-ECE 2021 Oral Presentation


Title: A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands
Presenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary Center
Session Date/Time: Wednesday, May 26, 2021, 8:30 a.m. – 9:30 a.m. EDT


e-ECE 2021 e-


Poster Presentations


Title: Safety Results from MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults with Acromegaly
Presenter: Pamela Freda, M.D., Columbia University
Session Date/Time: Monday, May 24, 2021, 8:00 a.m. – 8:30 a.m. EDT

Title: Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results from the MPOWERED Trial
Presenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical Center
Session Date/Time: Tuesday, May 25, 2021, 8:00 a.m. – 8:30 a.m. EDT

Title: Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients with Acromegaly Who Are Inadequately Controlled with Monotherapy
Presenter: Maria Fleseriu, M.D., FACE, Professor, Medicine and Neurological Surgery, Director OHSU Northwest Pituitary Center
Session Date/Time: Tuesday, May 25, 2021, 8:00 a.m. – 8:30 a.m. EDT

Title: Improved Acromegaly Patient Satisfaction with Oral Octreotide Capsules Compared with Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
Presenter: Murray B. Gordon, M.D., Allegheny General Hospital
Session Date/Time: Wednesday, May 26, 2021, 8:00 a.m. – 8:30 a.m. EDT


AACE 2021


Oral Presentation


Title: Improved Quality of Life and Work Productivity in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial
Presenter: Nienke Biermasz, M.D., Ph.D., Leiden University Medical Center
Session Date/Time: Thursday, May 27, 2021, 1:30 p.m. – 1:45 p.m. EDT


AACE


2021 Late-Breaker e-Posters

–
Available online via the virtual e-Poster Gallery beginning May 26

Title: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients with Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial
Lead Author: Murray B. Gordon, M.D., Allegheny General Hospital

Title: Injection Site Reactions and Their Impact in Patients with Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED Trial
Lead Author: Murray B. Gordon, M.D., Allegheny General Hospital

To register and view the full schedules as well as abstracts, visit e-ECE’s website here and AACE’s website here.

Chiasma will sponsor a product theatre presentation at the AACE annual meeting titled “Understanding the Management of Acromegaly with MYCAPSSA® (octreotide) Delayed-Release Oral Capsules” on Wednesday, May 26 at 2:45 p.m. EDT. Anthony P. Heaney, M.D., Ph.D., Professor, UCLA, will lead the presentation and a live Q&A session.

About the MPOWERED™ Trial

The MPOWERED trial was a global, non-inferiority, randomized, open-label and active-controlled, 15-month trial intended to support approval of MYCAPSSA in the European Union. Chiasma completed enrollment of 146 adult acromegaly patients into the trial in June 2019, of which 92 patients were deemed responders to octreotide capsules per the protocol following a six-month run-in were randomized to either octreotide capsules (n=55) or injectable somatostatin receptor ligands (octreotide LAR or lanreotide autogel) (n=37), and then followed for an additional nine months. The trial was designed to evaluate the proportion of patients who maintain their biochemical response to octreotide capsules and patient-reported outcomes in patients treated with octreotide capsules, compared to patients treated with leading injectable somatostatin analogs.

About MYCAPSSA

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or 

www.fda.gov/medwatch

The full Prescribing Information for MYCAPSSA is available at 

www.MYCAPSSA.com

.

About Acromegaly

Acromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease. Chiasma estimates that approximately 8,000 adult acromegaly patients are chronically treated with somatostatin analog injections in the United States.

About Chiasma

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the data from the MPOWERED trial and the therapeutic potential of MYCAPSSA. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond the company’s control, that may cause actual events or results to differ materially from the company’s current expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could be affected by risks and uncertainties. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this information unless required by law.

Investor Relations and Corporate Communications:

Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
[email protected]

Media Relations:

Patrick Bursey
LifeSci Communications
646-876-4932
[email protected]



Posted on

Crescent Acquisition Corp Files Definitive Proxy in Connection with Proposed Business Combination With LiveVox Holdings, Inc.

Crescent Acquisition Corp Files Definitive Proxy in Connection with Proposed Business Combination With LiveVox Holdings, Inc.

SAN FRANCISCO–(BUSINESS WIRE)–
Crescent Acquisition Corp (NASDAQ: CRSA) (“Crescent”), a publicly-traded special purpose acquisition company, filed a definitive proxy statement relating to its previously announced proposed business combination (the “Business Combination”) with LiveVox Holdings, Inc. (“LiveVox”), a cloud-based provider of customer service and digital engagement tools.

Crescent will hold a special meeting in lieu of the 2021 annual meeting of its stockholders (the “Special Meeting”) to, among other things, allow its stockholders to vote to approve the proposed Business Combination. The Special Meeting is scheduled to be held on Wednesday, June 16th at 10 AM Pacific Time. The Special Meeting will be completely virtual and conducted via live webcast. Holders of record of Crescent common stock at the close of business on the record date of May 10, 2021 may vote at the Special Meeting.

If the proposals at the Special Meeting are approved, the parties anticipate that the Business Combination will close shortly thereafter, subject to the satisfaction or waiver (as applicable) of all other closing conditions. Upon the closing of the Business Combination, the parties expect that the combined company will operate as LiveVox Holdings, Inc., and that its Class A common stock, units and warrants will be listed on The Nasdaq Stock Market LLC under the symbols “LVOX,” “LVOXU” and “LVOXW,” respectively.

Crescent stockholders who need assistance voting or have questions regarding the Special Meeting may contact Crescent Acquisition Corp, 11100 Santa Monica Boulevard, Suite 2000, Los Angeles, CA 90025, by telephone at (310) 235-5900 or by email at [email protected], or Crescent’s proxy solicitor, Morrow Sodali LLC, 470 West Avenue, Stamford, CT 06902, by telephone at (800) 662-5200 (for individuals) or (203) 658-9400 (for banks and brokerages) or by email at [email protected].

About LiveVox

LiveVox, a portfolio company of Golden Gate Capital, is a leading cloud-based contact center platform. By seamlessly integrating omnichannel communications, customer relationship management (CRM), and workforce optimization (WFO), LiveVox delivers exceptional agent and customer experiences, while helping to reduce compliance risk. LiveVox’s reliable, easy-to-use technology enables effective engagement strategies on channels of choice to help drive contact center performance. Founded in 2000, LiveVox is headquartered in San Francisco with offices in Atlanta, Denver, St. Louis, Colombia, and Bangalore. To learn more, visit www.livevox.com.

About Crescent Acquisition Corp

Crescent is a special purpose acquisition company formed by Crescent Capital, Robert D. Beyer and Todd M. Purdy for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets.

IMPORTANT LEGAL INFORMATION

Additional Information about the Proposed Transaction and Where to Find It

This communication may be deemed solicitation material in respect of the proposed Business Combination between Crescent and LiveVox. The Business Combination will be submitted to the stockholders of Crescent and LiveVox for their approval. In connection with such stockholder vote, Crescent filed with the Securities and Exchange Commission (the “SEC”) a proxy statement on Schedule 14A and mailed a definitive proxy statement to its stockholders in connection with Crescent’s solicitation of proxies for the special meeting of the stockholders of Crescent to be held to approve the Business Combination. This communication does not contain all the information that should be considered concerning the proposed Business Combination and the other matters to be voted upon at the special meeting and is not intended to provide the basis for any investment decision or any other decision in respect of such matters. Crescent’s stockholders and other interested parties are urged to read the proxy statement, the amendments thereto, the definitive proxy statement and any other relevant documents that are filed or furnished or will be filed or will be furnished with the SEC carefully and in their entirety in connection with Crescent’s solicitation of proxies for the special meeting to be held to approve the Business Combination and other related matters, as these materials contain important information about LiveVox and Crescent and the proposed Business Combination. The definitive proxy statement is being mailed to the stockholders of Crescent as of the record date established for voting on the proposed Business Combination and the other matters to be voted upon at the special meeting. Such stockholders may also obtain copies of the proxy statement, without charge, at the SEC’s website at http://www.sec.gov, at Crescent’s website at http://www.crescentspac.com or by directing a request to Crescent Acquisition Corp, 11100 Santa Monica Blvd., Suite 2000, Los Angeles, CA 90025.

Forward-Looking Statements

This communication contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be made directly in this communication. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Crescent or LiveVox, as the case may be, as of the date of this communication, and may include, without limitation, changes in general economic conditions, including as a result of COVID-19, all of which are accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this communication constitute Crescent’s or LiveVox’s, as the case may be, judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this communication are subject to a number of factors, risks and uncertainties, some of which are not currently known to Crescent or LiveVox, that may cause Crescent’s or LiveVox’s actual results, performance or financial condition to be materially different from the expectations of future results, performance of financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions that Crescent or LiveVox, as the case may be, believe to be reasonable, there is no assurance that the expected results will be achieved. Crescent’s and LiveVox’s actual results may differ materially from the results discussed in forward-looking statements. Additional information on factors that may cause actual results and Crescent’s performance to differ materially is included in Crescent’s periodic reports filed with the SEC, including but not limited to Crescent’s annual report on Form 10-K for the year ended December 31, 2020. Copies of Crescent’s filings with the SEC are available publicly on the SEC’s website at www.sec.gov or may be obtained by contacting Crescent. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as of the date hereof, and neither Crescent nor LiveVox undertake any obligations to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

No Offer or Solicitation

This communication is for informational purposes only and does not constitute an offer or invitation for the sale or purchase of securities, assets or the business described herein or a commitment to Crescent or LiveVox with respect to any of the foregoing, and this filing shall not form the basis of any contract, nor is it a solicitation of any vote, consent, or approval in any jurisdiction pursuant to or in connection with the Business Combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Participants in Solicitation

Crescent and LiveVox, and their respective directors and executive officers, may be deemed participants in the solicitation of proxies of Crescent’s stockholders in respect of the Business Combination. Information about the directors and executive officers of Crescent and of LiveVox and more detailed information regarding the identity of all potential participants, and their direct and indirect interests, by security holdings or otherwise, are set forth in the proxy statement for the Business Combination. Additional information regarding the identity of all potential participants in the solicitation of proxies to Crescent’s stockholders in connection with the proposed Business Combination and other matters to be voted upon at the special meeting, and their direct and indirect interests, by security holdings or otherwise, are included in the proxy statement that Crescent filed with the SEC. Investors may obtain such information by reading such proxy statement.

Media:

For LiveVox:

Investors:

Alexis Waadt

Vice President, Head of Investor Relations

[email protected]

Michael Bowen and Ryan Gardella

ICR, Inc. for LiveVox

[email protected]

Media:

Katie Creaser

[email protected]

For Crescent Acquisition Corp:

Investors:

Lasse Glassen

Addo Investor Relations

[email protected]

424-238-6249

Media:

Bill Mendel

Mendel Communications

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Posted on

Movado Group, Inc. Announces Date of Conference Call and Webcast for First Quarter Fiscal Year 2022 Results

Movado Group, Inc. Announces Date of Conference Call and Webcast for First Quarter Fiscal Year 2022 Results

PARAMUS, N.J.–(BUSINESS WIRE)–
Movado Group, Inc. (NYSE: MOV) invites investors to listen to a broadcast of the Company’s conference call to discuss first quarter fiscal year 2022 earnings results on Thursday, May 27, 2021 at 9:00 a.m. Eastern Time. A press release detailing the Company’s first quarter fiscal year 2022 results will be issued before the market opens and prior to the call. The conference call will be hosted by Efraim Grinberg, Chairman and Chief Executive Officer, and Sallie DeMarsilis, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

Investors and analysts interested in participating in the call are invited to dial (877) 407-0784 and reference conference ID number 13719857 approximately ten minutes prior to the start of the call. The conference call will also be webcast live at www.movadogroup.com. The webcast will be archived online within one hour of the completion of the conference call and remain available for 90 days. Additionally, a telephonic replay of the call will be available from 12:00 p.m. ET on May 27, 2021 until 11:59 p.m. ET on June 10, 2021 and can be accessed by dialing (844) 512-2921 and entering replay access code 13719857#.

Movado Group, Inc. designs, sources, and globally di stributes MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, LACOSTE® and SCUDERIA FERRARI® watches and, for certain of these brands, jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.

ICR, Inc.

Investors:

Rachel Schacter/Allison Malkin

203-682-8200

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Other Manufacturing Textiles Specialty Luxury Cosmetics Manufacturing Retail Department Stores

MEDIA:

Posted on

Seedo Corp. Appoints Dr. Yahav Bleicher, A Recognized Expert with Extensive Experience in Extracts, Natural Foods, and Nutraceuticals, to Develop the Company’s Pharma Grade Saffron.

TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) —  Seedo Corp. (OTCQB: SEDO), today announced the appointment of Dr. Yahav Bleicher, an expert in his field, to be in charge of extracting and developing the company’s new line of products.

Dr. Bleicher brings with him decades of experience as a highly trained professional in the natural products’ industry, functional foods & beverages, and a unique specialization in nutraceuticals, extracts and application methods of botanicals and nutraceuticals.

Dr. Bleicher is a licensed pharmacist and herbalist whose been researching plants and formulations for years. He owns a degree in biochemistry and agriculture from the Hebrew University in Jerusalem and Israeli Volcanic Institute (ARO) where he led an Israeli invention of the extraction of Omega 3 from plants.

Commenting on the appointment, David Freidenberg, CEO, Seedo Corp., stated: “From a professional perspective, Yahav brings to Seedo Corp. a broad, practical experience with a variety of products, and an in-depth expertise in developing extracts, natural products and nutraceuticals. He is highly respected in his field, and we look forward to working with him in meeting our strategic goals.”

“I’m happy for this opportunity to contribute with my knowledge and vast experience to Seedo’s innovation and look forward to a fruitful research and development process” stated Dr. Bleicher.”

About Seedo:

Seedo Corp. (OTC: SEDO) is an agritech company that focuses on the research, development, and commercialization of agriculture products. Seedo’s technology is aimed at transforming the way agriculture is done by offering a responsible and sustainable way to grow crops in a world confronted by environmental challenges and dwindling earth reserves, diminishing water sources and unstable weather conditions.

Cautionary Note Regarding Forward-Looking Statements

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our ability to successfully execute a smooth transition of CFO functions as well as our ability to retain and recruit qualified executives; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Reports on Form 10-Q and in our Annual Report on Form 10-K, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Media Relations Contact:
David Freidenberg, Chief Executive Officer,
[email protected]
+1 (800) 608-6432

Attachment



Posted on

United Natural Foods Announces Virtual Investor Day

United Natural Foods Announces Virtual Investor Day

PROVIDENCE, R.I.–(BUSINESS WIRE)–
United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today announced that the Company will host a Virtual Investor Day on Thursday, June 24, 2021.

Members of UNFI’s leadership team will discuss the Company’s strategy for growth and multi-year financial outlook. The event will begin at 8:30 a.m. eastern time and be webcast live at the Investors section of the Company’s website www.unfi.com. An online archive of the webcast will be available for 120 days.

About United Natural Foods

UNFI is North America’s premier food wholesaler delivering the widest variety of products to customer locations throughout North America including natural product superstores, independent retailers, conventional supermarket chains, ecommerce retailers, and food service customers. By providing this deeper ‘full-store’ selection and compelling brands for every aisle, UNFI is uniquely positioned to deliver great food, more choices, and fresh thinking to customers everywhere. Today, UNFI is the largest publicly-traded grocery distributor in America. To learn more about how UNFI is Moving Food Forward, visit www.unfi.com.

INVESTOR CONTACT:

Steve Bloomquist

Vice President, Investor Relations

952-828-4144

KEYWORDS: Rhode Island United States North America

INDUSTRY KEYWORDS: Food/Beverage Retail

MEDIA: